<DOC>
	<DOCNO>NCT02473653</DOCNO>
	<brief_summary>Immune-based therapy ( vaccine ) new focus clinical investigation . These therapy try assist patient 's immune system ( system body protect u infection ) kill tumor . One form therapy dendritic cell combine HER-2/neu ( type protein over-expressed cancer ) vaccine . Dendritic cell immune cell tell immune system fight infection . In laboratory testing , cell may also help immune system attack tumor breast , kidney cancer skin cancer . The purpose research study determine possible safe administer '' vaccine patient HER2+ cancer .</brief_summary>
	<brief_title>Pilot Trial HER-2/Neu Pulsed DC1 Vaccine Patients With HER-2 Positive Metastatic Cancer</brief_title>
	<detailed_description>We demonstrate administration HER-2/neu pulse DC1 patient DCIS result strong immunologic response well clinical response brief 4 6 week neoadjuvant vaccination . In subsets patient cancer HER-2 over-expressed include subset breast , gastric , pancreatic , brain , lung , colon cancer . This trial design compassionate use HER-2/neu pulse DC1 patient metastatic HER-2 positive cancer , long standard option eliminate disease .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Age â‰¥ 18 year . 2 . Subjects active metastatic HER2 positive cancer , least 1+ IHC , already receive standard therapy exhaust treatment option . 3 . Subjects HER2 1+ need HLA 2 HLA A3 positive . There HLA restriction HER2 2+ 3+ . 4 . Women childbearing age negative pregnancy test document prior enrollment . 5 . Subjects ECOG Performance Status Score 0 1 ( Appendix D ) . 6 . Women childbearing potential must agree use medically acceptable form birth control ( medically accept method : birth control pill , condom spermicidal lubricant , intrauterine device , diaphragm ) participation study . 7 . Subjects voluntarily sign write Informed Consent accordance institutional policy content fully explain . 1 . Pregnant lactating female . 2 . Subjects positive HIV hepatitis C baseline self report . 3 . Subjects coagulopathies , include thrombocytopenia platelet count &lt; 75,000 , INR &gt; 1.5 partial thromboplastin time &gt; 50 sec 4 . Subjects major cardiac illness MUGA ECHO &lt; 50 % EF . 5 . Subjects preexist medical illness medication might interfere study determine PI . 6 . Subjects receive current therapy may suppress immune system , steroid , chemotherapy discretion PI .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>